Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814173 | 0.84 | DAO (0.65) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL2176203 | 0.84 | PARP1 (0.47) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL24459408 | 0.82 | PARP1 (0.46) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL12407032 | 0.82 | LOXL2 (0.49) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL24036135 | 0.82 | PARP1 (0.49) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL4083604 | 0.82 | PARP1 (0.46) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL10673042 | 0.81 | USP2 (0.47) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL2332640 | 0.81 | PARP1 (0.45) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL2331028 | 0.81 | DAO (0.47) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL13141068 | 0.79 | PARP1 (0.44) | PARP1DAOCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| US-10442828-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180305383-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-10-25 | — | — | US | disclosed |
| US-10072034-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170291917-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1444228-A2 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-09-04 | — | — | US | disclosed |
| WO-2003044015-A2 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2003-05-30 | — | — | WO | disclosed |
| US-4777179-A | HISTAMINE H2-ANTAGONIST | GLAXO GROUP LIMITED (GB) | 1988-10-11 | — | — | US | disclosed |
| US-4670448-A | ANTIINFLAMMATORY AGENTS, HISTAMINE H2-ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1987-06-02 | — | — | US | disclosed |
| EP-0027744-B1 | THIOPHENE DERIVATIVES, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-03-14 | — | — | EP | disclosed |
| US-4382929-A | HISTAMINE H2 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1983-05-10 | — | — | US | disclosed |
| EP-0027744-A1 | Thiophene derivatives, processes for the production thereof and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072034-B2 | Kinase inhibitors | SYK, LYN, BTK | PARP1 3468/4885DAO 3296/4885CA12 4840/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | PARP1 3954/4885DAO 3281/4885CA12 3596/4885 |
| US-20180305383-A1 | KINASE INHIBITORS | SYK, LTK, LTB4R | PARP1 2661/4885DAO 3015/4885CA12 4881/4885 |
| US-10442828-B2 | Kinase inhibitors | SYK, LTK, LTB4R | PARP1 2661/4885DAO 3015/4885CA12 4881/4885 |
| US-20170291917-A1 | KINASE INHIBITORS | SYK, LYN, BTK | PARP1 3468/4885DAO 3296/4885CA12 4840/4885 |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | GPR119, LIPA, DDC | PARP1 3914/4885DAO 7/4885CA12 2797/4885 |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | PARP1 3954/4885DAO 3281/4885CA12 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.